Showing 1211-1220 of 1614 results for "".
- Prism Vision Group Announces Launch of New Brandhttps://modernod.com/news/prism-vision-group-announces-launch-of-new-brand/2476726/Prism Vision Group, an ophthalmology administrative services care provider organization, was officially launched. The new entity is led by Steven Madreperla, MD, PhD, a practicing ophthalmologist and one of the founding partners of NJRetina, a specialty retina practice with roots that reac
- Allegro Announces Positive Results of Ex-US Proof-of-Concept Trial With ALG-1007 for Dry Eye Diseasehttps://modernod.com/news/allegro-ophthalmics-announces-positive-results-of-ex-us-proof-of-concept-trial-with-integrin-inhibitor-alg-1007-for-dry-eye-disease/2476583/Allegro Ophthalmics announced positive results of an ex-US proof-of-concept clinical trial of the new investigational ALG-1007 topical drop drug candidate in patients with dry eye disease (DED). The results were presented by Eric D. Donnenfeld, MD, last week at the 2019 American Society of Catara
- Jefferson and Wills Eye Launch World’s First Center Focused on Connections Between the Eye and the Brainhttps://modernod.com/news/jefferson-and-wills-eye-launch-worlds-first-center-focused-on-connections-between-the-eye-and-the-brain/2476574/Thomas Jefferson University, in partnership with Wills Eye Hospital and thanks to the generosity of several prescient philanthropists, has launched the world’s first center focused on the visual signatures of neurological diseases. The William H. Annesley, Jr., MD ’48 EyeBrain Center will explore
- Eyenovia Announces Presentation of Successful Phase 3 Studies at the ASCRShttps://modernod.com/news/eyenovia-announces-presentation-of-successful-phase-3-studies-at-the-ascrs/2476557/Eyenovia announced the safety and efficacy results from the company’s two phase 3 trials, MIST-1 and MIST-2, for pharmacologic mydriasis (pupil dilation). The results were presented by David Wirta, MD, from the podium during the joint ASCRS-ASOA annual meeting, on May 5, 2019 in S
- Results of Lumega-Z Data to be Presented at ARVOhttps://modernod.com/news/results-of-lumega-z-data-to-be-presented-at-arvo/2476474/Guardion Health Sciences Scientific Advisory Board member William Sponsel, MD, will be presenting an abstract at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting in Vancouver, Canada, which will be held from April 28, 2019 to May 2, 2019. The abstract is titled
- Children’s Hospital Los Angeles Receives $1.6M Grant to Study Retinoblastomahttps://modernod.com/news/childrens-hospital-los-angeles-receives-1-6m-grant-to-study-retinoblastoma/2476397/Retinoblastoma is a tumor of the retina that generally affects children under 5 years of age and accounts for approximately 4% of childhood cancers. If not diagnosed early, retinoblastoma may result in loss of one or both eyes and can be fatal. David Cobrinik, MD, PhD, of The Saban Researc
- Zeiss Receives FDA Clearance for Epithelial Thickness Mapping for CIRRUS HD-OCThttps://modernod.com/news/zeiss-receives-fda-clearance-for-epithelial-thickness-mapping-for-cirrus-hd-oct/2476359/Zeiss announced that it has received FDA 510(k) clearance for the CIRRUS HD-OCT platform, expanding the capabilities of its Anterior Segment Premier Module to include epithelial thickness mapping (ETM). According to refractive specialist John Doane, MD, of Discover Vision Center in Kansas
- FDA Commissioner Gottlieb Announces Efforts to Improve Assessment of REMS Programshttps://modernod.com/news/fda-commissioner-gottlieb-announces-efforts-to-improve-assessment-of-rems-programs/2479604/In an FDA statement, Commissioner Scott Gottlieb, MD, announced efforts to improve the quality of the information used to assess the effectiveness of Risk Evaluation and Mitigation Strategy (REMS) programs in supporting the safe use of medications. In making decisions about whether the ben
- Mount Sinai Recruits Internationally Recognized Ophthalmologists to Expand Leadershiphttps://modernod.com/news/mount-sinai-recruits-internationally-recognized-ophthalmologists-to-expand-leadership/2479609/Mount Sinai Health System announced the appointment of two new faculty members to expand leadership in the Department of Ophthalmology. Louis R. Pasquale, MD, FARVO, has been named Site Chair of Ophthalmology at The Mount Sinai Hospital and Mount Sinai Queens and will also serve as Vice Chair of
- Clearside Presents Additional Analyses of PEACHTREE Clinical Trial Data in Support of Xipere in Treating Uveitic Macular Edemahttps://modernod.com/news/clearside-presents-additional-analyses-of-peachtree-clinical-trial-data-in-support-of-xipere-in-treating-uveitic-macular-edema/2476155/Clearside Biomedical recently announced that additional data from PEACHTREE, the company’s pivotal phase 3 trial of Xipere (formerly suprachoroidal CLS-TA) in patients with uveitic macular edema, were presented by Rahul N. Khurana, MD, Vitreoretinal Surgeon at Northern California